H. Lundbeck A/S (commonly known simply as Lundbeck) is a Danish international pharmaceutical company engaged in the research and development, production, marketing, and sale of drugs for the treatment of disorders in the central nervous system (CNS), including depression, schizophrenia, Alzheimer's disease and Parkinson's disease.

Headquartered in Copenhagen, Denmark, Lundbeck has international production facilities in Denmark, Italy and France and affiliates or sales offices in more than 50 countries. Lundbeck employs around 5,000 people globally (as of 2017), and the company's products are registered in more than 100 countries worldwide

In 2017, the company's revenue was DKK 17.2 billion (€2.3 billion).

Lundbeck is listed on the Copenhagen Stock Exchange (CSE).

Lundbeck is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

maceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)